Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings

References

• Damiani G, Bragazzi NL, Aksut CK, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;8:741.
   Web of Science ®Google Scholar
• Laughter MR, Maymone MBC, Karimkhani C, et al. The burden of skin and subcutaneous diseases in the United States from 1990 to 2017. JAMA Dermatol. 2020;156(8):874–881.
   PubMed Web of Science ®Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961–967 e5.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–485.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Conti A, Damiani G, Ruggeri R, et al. Switching infliximab in psoriatic patients during COVID-19 pandemics: a real-life retrospective study comparing intra-versus interclass switching strategies. Dermatol Ther. 2021;34(5):e15088.
   PubMed Web of Science ®Google Scholar
• Kimberly H, LH RS, Steven RF. Psoriasis treatment cost comparison: biologics versus home phototherapy. Am J Pharm Benefits. 2018;10(1):18–21.
   Web of Science ®Google Scholar
• Wu JJ, Guerin A, Gauthier G, et al. Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. J Dermatolog Treat. 2017;28(4):290–298.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14(5):377–388.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Gilligan AM, Tran O, et al. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. J Dermatolog Treat. 2021;32(1):56–63.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310.
   PubMed Web of Science ®Google Scholar
• Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89–95.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824–830 e2.
   PubMed Web of Science ®Google Scholar
• Reiner B. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value: condition update: final evidence report. Boston, Massachusetts: Institute for Clinical and Economic Review, 2018.
   Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679.
   PubMed Web of Science ®Google Scholar
• Graubard BI, Korn EL. Predictive margins with survey data. Biometrics. 1999;55(2):652–659.
   PubMed Web of Science ®Google Scholar
• Greene WH. Econometric analysis. Upper Saddle River: Pearson Education India; 2003.
   Google Scholar
• Taltz [package insert]. Indianapolis: Eli Lilly and Company; 2016.
   Google Scholar
• Humira [package insert]. North Chicago, IL: Abbvie Inc.; 2002.
   Google Scholar
• Blauvelt A, Shi N, Zhu B, et al. Comparison of health care costs among patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab. J Manag Care Spec Pharm. 2019;25(12):1366–1376.
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–251.
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360–368.
   PubMed Web of Science ®Google Scholar
• Driessen RJ, Bisschops LA, Adang EM, et al. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol. 2010;162(6):1324–1329.
   PubMed Web of Science ®Google Scholar
• Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46–54.
   PubMedGoogle Scholar